Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma

Huang, Honghui; Xiao, Fei; Han, Xiao; Zhong, Liang; Zhong, Hua; Xu, Lan; Zhu, Jianyi; Ni, Beiwen; Liu, Jia; Fang, Yi; Zhang, Minyue; Shen, Lijing; Wang, Ting; Li, Jianjun; Shi, Yang; Chen, Yumei; Zheng, Luying; Liu, Qiang; Chen, Fangyuan; Wang, Jianmin

doi:10.1097/mnm.0000000000000496

Cited by 16 publications

(14 citation statements)

References 35 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also recorded the SUV max value of patients using PET-CT scan. PET-CT is the recommended imaging method to be used clinically when evaluating lymphoma patients [25, 26], and the SUV max value showed correlation with prognosis and lymphoma recurrence [27–29]. Our data showed that RasGRP4 expression was positively correlated with the SUV max value, supporting the association with high-risk IPI groups, further demonstrating the prognostic value of RasGRP4.…”

Section: Discussionsupporting

confidence: 68%

The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

Background This study aimed to confirm that blocking RasGRP4 can effectively slow down the growth of DLBCL both in vitro and in vivo and ascertain the role of RasGRP4 in the prognosis of DLBCL clinically. Methods RasGRP4 expression levels were examined in benign tissues and lymphomas. In order to verify somatic mutation in RasGRP4 gene, cDNA sequencing was performed in DLBCL patients. RasGRP4-dependent cell proliferation, mitochondrial membrane potential, oxidative stress levels and signaling pathway changes were measured by knockdown of RasGRP4. Tumor growth was monitored in xenografted lymphoma model. Clinical data were collected to confirm the role of RasGRP4 in DLBCL. Results RasGRP4 expression was significantly elevated in DLBCL while no somatic mutations were detected of this gene in DLBCL patients. Decreased RasGRP4 significantly inhibited cell proliferation by simultaneously reducing mitosis and promoting apoptosis and increased the oxidative stress levels. Mechanistically, reduced expression of RasGRP4 decreased ERK while increased JNK expression in SUDHL-4 cells. Knockdown of RasGRP4 also significantly inhibited tumor formation in vivo. Furthermore, RasGRP4 expression levels were significantly higher in patients with larger DLBCL lesions ( P = 0.0004), high-risk international prognostic index score groups ( P = 0.0042), and its expression was positively correlated with maximum standardized uptake value in DLBCL ( P = 0.0004). Conclusions These findings indicate the oncogenic role of RasGRP4 in DLBCL, suggesting it as a prognostic biomarker and potential therapeutic target in DLBCL. Electronic supplementary material The online version of this article (10.1186/s12964-019-0415-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 68%

The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A Chinese study on a group of lymphoma patients showed that post-treatment SUVmax values were significantly correlated with post-treatment CRP values [36]. By contrast, a previously mentioned study demonstrated that baseline SUVmax was weakly correlated with CRP (r = 0.215, p = 0.011) [34].…”

Section: Discussionmentioning

confidence: 94%

“…The authors of a meta-analysis concerning correlations between FDG uptake and Ki67 reported significant heterogeneity in HNC cases [33]. Furthermore, pretreatment SUVmax was significantly higher in patients with enhanced Ki67 expression in comparison to those with low Ki67 expression, but the study concerned diffuse large B-cell lymphoma [34]. Surov et al reported that SUVmax was moderately correlated with Ki67 expression and therefore cannot be used as a surrogate marker for tumor proliferation [35].…”

Section: Discussionmentioning

confidence: 99%

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Samołyk-Kogaczewska¹,

Sierko

Dziemiańczyk-Pakieła

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background: The novel hybrid of positron emission tomography/magnetic resonance (PET/MR) examination has been introduced to clinical practice. The aim of our study was to evaluate PET/MR usefulness in preoperative staging of head and neck cancer (HNC) patients (pts); (2) Methods: Thirty eight pts underwent both computed tomography (CT) and PET/MR examination, of whom 21 pts underwent surgical treatment as first-line therapy and were further included in the present study. Postsurgical tissue material was subjected to routine histopathological (HP) examination with additional evaluation of p16, human papillomavirus (HPV), Epstein-Barr virus (EBV) and Ki67 status. Agreement of clinical and pathological T staging, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of CT and PET/MR in metastatic lymph nodes detection were defined. The verification of dependences between standardized uptake value (SUV value), tumor geometrical parameters, number of metastatic lymph nodes in PET/MR and CT, biochemical parameters, Ki67 index, p16, HPV and EBV status was made with statistical analysis of obtained results; (3) Results: PET/MR is characterized by better agreement in T staging, higher specificity, sensitivity, PPV and NPV of lymph nodes evaluation than CT imaging. Significant correlations were observed between SUVmax and maximal tumor diameter from PET/MR, between SUVmean and CT tumor volume, PET/MR tumor volume, maximal tumor diameter assessed in PET/MR. Other correlations were weak and insignificant; (4) Conclusions: Hybrid PET/MR imaging is useful in preoperative staging of HNC. Further studies are needed.

show abstract

“…The clinical roles of FDG PET/CT scan in diagnosis, staging, monitoring of treatment and prediction of prognosis in patients with lymphoma have been reported [ 7 - 11 ]. The maximal SUV of the primary tumor has been previously demonstrated to be of prognostic values, because of easy accessibility and high reproducibility [ 12 , 13 ]. However, maximal SUV solely recorded intensity of FDG uptake in the most aggressive cells, without reflecting the volumetric concept.…”

Section: Discussionmentioning

confidence: 99%

“…The standardized uptake value (SUV) is the most commonly used semi-quantitative parameter in FDG PET/CT. Higher maximal SUV in the lesion has been proved to be of prognostic significance in patients with DLBCL [ 12 , 13 ]. Beyond SUV, with the development of software programs, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have recently been found to play an important role in the prediction of patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy

et al. 2017

View full text Add to dashboard Cite

PurposeThe purpose of this study was to determine the prognostic significance of metabolic parameters on pre-treatment 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT), in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-containing therapy.Materials and MethodsFrom September 2009 to December 2014, DLBCL patients who had received FDG PET/CT scans for staging were enrolled. The maximal standardized uptake value of tumor (SUVt) was recorded. The metabolic tumor volume (MTV) was the volume of lesion with an elevated SUV greater than 2.5. The total lesion glycolysis (TLG) was the sum of the products of MTV and mean SUV in all measured lesions. Univariate and multivariate analyses were used to assess the prognostic significance of maximal SUVt, total MTV, TLG and other clinical parameters.ResultsThere were 118 patients enrolled in this study. The median follow-up time was 28.7 months. The 5-year progression-free survival (PFS) for patients with higher and lower total MTV was 32.3% and 66.0% respectively (p = 0.0001). The 5-year overall survival (OS) for patients with higher and lower total MTV was 34.3% and 69.9% respectively (p < 0.0001). Multivariate analysis revealed, besides IPI, that total MTV was independently predictive for PFS (HR: 2.31, 95% CI: 1.16 – 4.60, p = 0.0180) and OS (HR: 2.38, 95% CI: 1.12 – 5.04, p = 0.024). TLG and maximal SUV of tumor were not independent prognostic factors.ConclusionsAn elevated total MTV was a predictor for shorter PFS and OS in patients with DLBCL receiving rituximab-containing therapy, independent of IPI.

show abstract

Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma

Abstract: Supplemental Digital Content is available in the text.

Cited by 16 publications

References 35 publications

The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma

The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy

Contact Info

Product

Resources

About